Medicare Enrolled
Dr. Carlos Rubin De Celis, MD
Medical Oncology · Austin, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rubin De Celis from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rubin De Celis?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rubin De Celis
Dr. Carlos Rubin De Celis is a medical oncology specialist in Austin, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Rubin De Celis performed 36,102 Medicare services across 2,616 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rubin De Celis received a total of $915 from 21 pharmaceutical and/or device companies across 37 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rubin De Celis is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 24% volume in TX
$915 industry payments
Medicare Practice Summary
Medicare Utilization ↗36,102
Medicare services
Top 24% in TX for medical oncology
2,616
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,900 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
15,700 | $2 | $20 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
8,500 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 3,120 | $16 | $66 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,000 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
865 | $8 | $20 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
832 | $8 | $36 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
810 | $10 | $64 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
399 | $9 | $56 |
| Injection, granisetron hydrochloride, 100 mcg | 360 | $0 | $24 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
347 | $6 | $31 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
296 | $92 | $368 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
294 | $60 | $250 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 219 | $3 | $373 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
192 | $83 | $1,348 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
187 | $2 | $13 |
| Immunoglobulin light chain measurement A blood test that measures the levels of immunoglobulin light chains, which are proteins produced by plasma cells. |
178 | $17 | $60 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
170 | $107 | $707 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
157 | $24 | $157 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
139 | $13 | $60 |
| Iron level test | 136 | $6 | $27 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
136 | $9 | $35 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 131 | $20 | $128 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
122 | $11 | $96 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
106 | $52 | $313 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
105 | $93 | $357 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
104 | $2 | $19 |
| Reticulated platelet measurement A blood test that measures the level of young, newly formed platelets in the body. |
98 | $35 | $143 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
95 | $6 | $431 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
89 | $23 | $161 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
79 | $12 | $108 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
68 | $10 | $75 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
65 | $59 | $247 |
| Beta-2 microglobulin level test A blood test that measures the level of beta-2 microglobulin, a protein produced by cells in the body. |
63 | $16 | $96 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
63 | $59 | $211 |
| Serum protein measurement A blood test that measures the total amount of protein in the serum. It helps evaluate overall health and nutritional status. |
62 | $11 | $99 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
62 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
62 | $6 | $34 |
| Immunologic analysis of serum A laboratory test that uses immunologic techniques to analyze components in a blood serum sample. |
58 | $29 | $108 |
| Serum immunofixation test A laboratory test that analyzes a blood serum sample to identify specific abnormal proteins. The procedure uses an immunologic technique to detect and characterize these proteins. |
58 | $22 | $160 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
58 | $1 | $7 |
| PSA test (prostate cancer screening) | 49 | $18 | $94 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
47 | $16 | $100 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
46 | $27 | $256 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
46 | $52 | $344 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 41 | $342 | $1,722 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
35 | $16 | $80 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
34 | $24 | $145 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
32 | $19 | $99 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
30 | $46 | $289 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $123 | $565 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
27 | $1 | $19 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
21 | $75 | $264 |
| Automated red blood cell count with calculations A blood test that automatically counts red blood cells and performs additional calculations to assess blood health. |
20 | $5 | $26 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
20 | $31 | $247 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
16 | $15 | $96 |
| New patient office visit, complex (60-74 min) | 12 | $175 | $709 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
12 | $94 | $470 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.9% high complexity
82.9% medium
15.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$915
Total received (2020-2024)
Avg $183/year across 5 years
Bottom 28% in TX for medical oncology
21
Companies
37
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$898 (98.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$17 (1.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$241
2023
$315
2022
$81
2021
$217
2020
$62
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$233
Phathom Pharmaceuticals, Inc.
$120
Cumberland Pharmaceuticals, Inc.
$71
Dova Pharmaceuticals
$46
Celgene Corporation
$41
PFIZER INC.
$40
Seagen Inc.
$39
GENZYME CORPORATION
$38
Gilead Sciences, Inc.
$36
JAZZ PHARMACEUTICALS INC.
$34
Daiichi Sankyo Inc.
$27
Adaptive Biotechnologies Corporation
$27
TAIHO ONCOLOGY, INC.
$25
Incyte Corporation
$21
ADC Therapeutics America, Inc.
$20
NESTLE HEALTHCARE NUTRITION INC.
$19
Bayer HealthCare Pharmaceuticals Inc.
$18
Eisai Inc.
$18
E.R. Squibb & Sons, L.L.C.
$17
Emmaus Medical, Inc.
$14
Janssen Biotech, Inc.
$12
Top 3 companies account for 46.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · CABLIVI · DARZALEX · Doptelet · ELIQUIS · ENJAYMO · Endari · Enhertu · Fabhalta · KISQALI · LONSURF · Lenvima · Nubeqa · OPDIVO · PADCEV · PEMAZYRE · PROMACTA · Pomalyst · REBLOZYL · SCEMBLIX · Trodelvy · VIBATIV · VOQUEZNA · VYXEOS · ZENPEP · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
26
Per 100K population
2.0
County median income
$97,169
Nearest hospital
ASCENSION SETON MEDICAL CENTER AUSTIN
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Rubin De Celis is a mixed practice specialist, with above-average Medicare volume (top 24% in TX), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Rubin De Celis experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Rubin De Celis performed 15,700 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rubin De Celis receive payments from pharmaceutical companies?
Yes. Dr. Rubin De Celis received a total of $915 from 21 companies across 37 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rubin De Celis's costs compare to other medical oncologists in Austin?
Dr. Rubin De Celis's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rubin De Celis) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Austin
Browse medical oncologists in Austin ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Phathom Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Phathom Pharmaceuticals, Inc.
By company
Cumberland Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Cumberland Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology